|Bid||0.00 x 1000|
|Ask||0.00 x 1000|
|Day's Range||33.80 - 37.20|
|52 Week Range||7.37 - 47.22|
|Beta (5Y Monthly)||1.50|
|PE Ratio (TTM)||299.32|
|Earnings Date||Nov 05, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||44.21|
BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of a portfolio of class-defining bioproduction products and services for cell and gene therapies, today announced the promotion of Marcus Schulz to the position of Chief Revenue Officer. He was previously Vice President of Global Sales.
Wasatch Advisors, an employee-owned investment manager, published its ‘Wasatch Micro Cap Value Fund’ third-quarter 2020 Investor Letter – a copy of which can be downloaded here. A return of 11.62% was recorded by the fund for the Q3 of 2020, above its Russel Microcap benchmark that returned 3.69%. You can view the fund’s top 10 […]
Despite MedTech industry's bright prospects in 2021, investors should be wary of stocks like BLFS, STAA and TGTX, given their unfavorable Zacks Rank and weak fundamentals.